Posts Tagged ‘semaglutide’

Is the glass half full? Or 99% empty? The metaphorical glass in this case is the number of people with a legitimate indication for the remarkable prescription drug generically known as semaglutide. Ivy Shi et al presented an elegant answer at the AHA Scientific Sessions this week and simultaneously published it in JAMA Cardiology. They […]

With the opening of ObesityWeek 2024, it’s worth stopping to consider the radically different situation for obesity medicine today in comparison to a few years ago. Obesity is becoming the new hypertension, says Lou Aronne. He called for it in 2017 and now it’s coming true. Aronne is a past president of the Obesity Society […]

As we travel to San Antonio for ObesityWeek 2024 (OW2024) one of the principal threads we want to explore is the expanding scope of GLP-1 therapy benefits. The narrative is a moving target. We won’t have the abstracts in hand for another day. But news this week makes it clear that we have barely gotten […]

It seems that both Novo Nordisk and Eli Lilly are dreaming of a bigger ban on competition for their wildly successful obesity drugs. With semaglutide and tirzepatide, they have valuable assets that meet a tremendous medical need. And they really do not like the compounding pharmacies taking big bites from their apples. So this week, […]

Adolescence is hard. With respect to mental health, especially of late, the environment is especially harsh. Even harsher if an adolescent is living with obesity. So a recent study in JAMA Pediatrics showing teens with obesity are having fewer suicidal thoughts when they get a GLP-1 is welcome news. Authors Liya Kerem and Joshua Stokar […]

New observational research in Addiction suggests that the rates of drug and alcohol use might be lower by as much as half when people are taking GLP-1s. Specifically, half as many people with alcohol use disorder had episodes of intoxication if they were taking a GLP-1. Among people with opioid use disorder, the rate of […]

Caution is wise when observational studies compete for our attention. But this one, from JAMA Network Open, is intriguing. In a recent analysis of 33,006 persons with both type 2 diabetes and opioid use disorder, researchers found a signal that semaglutide might lower the risk of opioid overdoses by as much as two-thirds. “It’s a […]

Late yesterday, FDA announced that Lilly’s tirzepatide shortage is officially over. Both Mounjaro and Zepbound are fully available in all marketed strengths and dosage forms. “The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in shortage since 2022 […]

It was an interesting day that we spent talking with health policy makers in the Senate yesterday. Refreshing in a way, because the conversations about obesity are so different from the conversations we were having just a few years ago. Not a single person raised the false issue of “personal responsibility” for “being obese.” Only […]

It’s true. We have been getting some pretty good news about GLP-1s lately. In persons with prediabetes and obesity, tirzepatide was 94% effective at preventing the development of diabetes. In the SELECT study, semaglutide for obesity might have cut COVID fatalities by a third. So a little exuberance about the potential of GLP-1 medicines is […]